The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Naiara Martínez-Vélez(Navarre Institute of Health Research), Marta M. Alonso(BioCruces Health research Institute), Jaime Gállego Pérez‐Larraya(Navarre Institute of Health Research), Maider Varela-Guruceaga(Inserm), José A. Martinez‐Climent(Marqués de Valdecilla University Hospital), Javier Aristu(Memorial Sloan Kettering Cancer Center), Michelle Monje(Howard Hughes Medical Institute), Chris Jones(North Carolina State University), Lucía Marrodán(Navarre Institute of Health Research), Marc García-Moure(Navarre Institute of Health Research), Juàn Fueyo(The University of Texas MD Anderson Cancer Center), Virginia Laspidea(Clinica Universidad de Navarra), Eric H. Raabe(Johns Hopkins University), Sonia Tejada-Solís(Navarre Institute of Health Research), Ricardo Díez-Valle(Navarre Institute of Health Research), Marisol González-Huarriz(Navarre Institute of Health Research), Hervé Chneiweiss(Centre National de la Recherche Scientifique), Elias A. El-Habr(Laiko General Hospital of Athens), Hong Jiang(The University of Texas MD Anderson Cancer Center), Candelaria Gomez‐Manzano(The University of Texas MD Anderson Cancer Center), Alan Mackay(Institute of Cancer Research), Miguel Marigil(Navarre Institute of Health Research), María J. García‐Barchino(Navarre Institute of Health Research), Montse Puigdelloses(Navarre Institute of Health Research), Luis Ramos(Navarre Institute of Health Research), Oren J. Becher(Icahn School of Medicine at Mount Sinai), Marta Zalacaín(Navarre Institute of Health Research), Ana Patiño‐García(Navarre Institute of Health Research), Marie Pierre Junier(Centre National de la Recherche Scientifique), Guillermo Aldave(Baylor College of Medicine)
Nature Communications
May 28, 2019
Cited by 143


Related Papers